Financial News
Articles published by Silo Pharma, Inc.
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
December 18, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
November 29, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
November 18, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
October 31, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
September 10, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
August 14, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
August 07, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
July 19, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
July 18, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
June 07, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
June 05, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
May 14, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
April 10, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
February 28, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
February 01, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
January 24, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
January 04, 2024
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
December 28, 2023
From Silo Pharma, Inc.
Via GlobeNewswire
Tickers
SILO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.